Benzinga | Dec 7, 2021 01:03PM EST

Mix & Match Pfizer, AstraZeneca COVID-19 Vaccine With Moderna Shows Improved Immune Response

A British study evaluating mixing COVID-19 vaccines showed a better immune response in people after the first dose of AstraZeneca Plc (NASDAQ:AZN) or Pfizer Inc (NYSE:PFE) / BioNTech SE (NASDAQ:BNTX) shots followed by Moderna Inc's (NASDAQ:MRNA) nine weeks later.

* AstraZeneca-Oxford vaccine followed by a Moderna or Novavax Inc (NASDAQ:NVAX) shot showed higher antibodies and T-cell responses versus two doses of AstraZeneca-Oxford.

* The study of 1,070 volunteers also found that a dose of the Pfizer-BioNTech vaccine followed by a Moderna shot was better than two doses of the standard Pfizer-BioNTech course.

* Pfizer-BioNTech followed by Novavax induced higher antibodies than the two-dose Oxford-AstraZeneca schedule, although this schedule induced lower antibody and T-cell responses than the two-dose Pfizer-BioNTech schedule.

* According to the Oxford University study published in the Lancet medical journal, no safety concerns were raised.

* Related Link: Johnson & Johnson Booster COVID-19 Shot Shows Encouraging Action After Pfizer/BioNTech Jab.

* The study supports the flexible use of these vaccines in primary immunization schedules, necessary to help the rapid deployment of these vaccines, especially in low- and middle-income countries.

* Photo by Johaehn from Pixabay